# Rivas Capital

> Rivas Capital is a VC fund in Cambridge backing Biotechnology and Health Care. See 25 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Cambridge, United States
- Total investments: 25
- Last investment: Jan 2024
- Lead investor: 20%
- Last updated: Aug 2026
- Website: http://www.rivascap.com

Rivas Capital is a private investment firm focused on long-term principal investments in breakthrough technology businesses.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 8 | 32% |
| Health Care | 7 | 28% |
| Medical | 4 | 16% |
| Artificial Intelligence | 3 | 12% |
| AgTech | 2 | 8% |

41 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 6 | 24% |
| Seed | 4 | 16% |
| Funding Round | 4 | 16% |
| Series B | 3 | 12% |
| Series D | 3 | 12% |

8 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 14 | 56% |
| Germany | 1 | 4% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Inari | Inari is a biotech seed company that embraces diversity in every aspect of its business to drive innovation and help build a new food system. Our technology matches the complexity of nature using predictive design and multiplex gene editing to unlock the full potential of seed. We are always innovating, pushing the boundaries of what’s possible.Our SEEDesign platform is our point of distinction, using unsurpassed technology to enhance any crop for any geography to develop step-change products with a clear go-to-market approach. | $103M | Series F | Jan 30, 2024 |  |
| Greenlight Biosciences | GreenLight Biosciences is an integrated life sciences company with a cutting-edge platform to deliver higher-quality RNA at a lower cost and more quickly than was ever before possible. GreenLight develops RNA products and collaborates with industry leaders to advance vaccine development, pandemic preparation, crop management, plant protection andsupport the health of bees and other pollinators. | $109M | Post-IPO Equity | Aug 12, 2022 |  |
| Clarify Health Solutions | Clarify Health enables health systems to deliver more satisfying and efficient care through a software and analytics platform that provides real-time insights and nudges to patients, family members, and clinicians. The solution optimizes episode of care workflows. Real-time tracking and machine learning analytics guide patients throughdynamically-updated care journeys. Patients and family members benefit from greater transparency, personalization, and engagement. Clinicians can focus on the highest need patients while the platform streamlines workflows and simplifies tasks. | $150M | Series D | Apr 05, 2022 |  |
| NextRNA Therapeutics | NextRNA Therapeutics creates targeted therapeutics with the aim of discovering novel ncRNAs that cause disease. The company was founded in 2020 and is headquartered in Cambridge, Massachusetts. | $46.8M | Series A | Mar 01, 2022 |  |
| Greenlight Biosciences | GreenLight Biosciences is an integrated life sciences company with a cutting-edge platform to deliver higher-quality RNA at a lower cost and more quickly than was ever before possible. GreenLight develops RNA products and collaborates with industry leaders to advance vaccine development, pandemic preparation, crop management, plant protection andsupport the health of bees and other pollinators. | $125.5M | Post-IPO Equity | Feb 03, 2022 |  |
| Comgy | Comgy digitizes the measurement, visualization and billing of heat, water and electricity consumption in real estate. | $27.4M |  | Nov 09, 2021 |  |
| Comgy | Comgy digitizes the measurement, visualization and billing of heat, water and electricity consumption in real estate. | $29M | Series B | Nov 09, 2021 |  |
| Inari | Inari is a biotech seed company that embraces diversity in every aspect of its business to drive innovation and help build a new food system. Our technology matches the complexity of nature using predictive design and multiplex gene editing to unlock the full potential of seed. We are always innovating, pushing the boundaries of what’s possible.Our SEEDesign platform is our point of distinction, using unsurpassed technology to enhance any crop for any geography to develop step-change products with a clear go-to-market approach. | $208M | Series D | May 12, 2021 |  |
| Clarify Health Solutions | Clarify Health enables health systems to deliver more satisfying and efficient care through a software and analytics platform that provides real-time insights and nudges to patients, family members, and clinicians. The solution optimizes episode of care workflows. Real-time tracking and machine learning analytics guide patients throughdynamically-updated care journeys. Patients and family members benefit from greater transparency, personalization, and engagement. Clinicians can focus on the highest need patients while the platform streamlines workflows and simplifies tasks. | $115M | Series C | Mar 16, 2021 |  |
| Regenacy Pharmaceuticals | Regenacy Pharmaceuticals they give services to treat diabetic and other peripheral neuropathies. |  | Series A | Mar 25, 2020 |  |

10 of 25 investments shown.

## Co-investors
- [Cobro Ventures](https://shizune.co/investors/profile/cobro-ventures) — VC Fund, 6 deals together
- [Flagship Pioneering](https://shizune.co/investors/profile/flagship-ventures) — VC Fund, 4 deals together
- [Boston Seed Capital](https://shizune.co/investors/profile/boston-seed-capital) — VC Fund, 3 deals together
- [Fall Line Capital](https://shizune.co/investors/profile/fall-line-capital) — VC Fund, 3 deals together
- [S2G Investments](https://shizune.co/investors/profile/s2g-ventures) — VC Fund, 3 deals together
- [Sigmas Group](https://shizune.co/investors/profile/sigmas-group) — VC Fund, 3 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Rivas Capital invest in?

Rivas Capital invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Seed stage. Most of the 25 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Rivas Capital last invest?

The most recent investment recorded for Rivas Capital closed in Jan 2024. Shizune tracks 25 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co